Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 4/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20902102 | 0.90 | GAA (0.51) | GAAALDH1A1CA2CYP1A2TERT | |
| SCHEMBL14237910 | 0.90 | GAA (0.51) | GAAALDH1A1CA2CYP1A2TERT | |
| SCHEMBL19485973 | 0.82 | GAA (0.58) | GAAALDH1A1SMN1; SMN2CYP1A2RECQL | |
| SCHEMBL14238197 | 0.74 | CA1 (0.45) | GAAALDH1A1CA2 | |
| SCHEMBL26265633 | 0.74 | CA1 (0.45) | GAAALDH1A1CA2 | |
| SCHEMBL19485799 | 0.74 | GAA (0.63) | GAAALDH1A1SMN1; SMN2CA2CYP1A2 | |
| SCHEMBL21440850 | 0.74 | DPP7 (0.46) | CA2DPP7TLR2GNAI3GNAO1 | |
| SCHEMBL22536411 | 0.74 | TLR2 (0.45) | GAAALDH1A1CA2TLR2 | |
| SCHEMBL17337705 | 0.74 | CA2 (0.49) | GAAALDH1A1CA2CYP1A2 | |
| SCHEMBL17337709 | 0.74 | CA2 (0.49) | GAAALDH1A1CA2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | CD74, CD63, CD47 | GAA 438/4885ALDH1A1 868/4885SMN1; SMN2 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.